Ticker LaunchUplisting · EVO
Evotec SE
Formerly Evotec AG
Evotec SE (EVO), already reporting to the SEC, moved up to Nasdaq Global Select on Nov 5, 2021 with an offering at $21.75 per ADS raising $435M. BofA Securities was lead-left underwriter, joined by Morgan Stanley, Citigroup and Jefferies and others. Freshfields and Kirkland & Ellis advised the company and Latham & Watkins advised the underwriters.
Evotec SE is a drug discovery and development partner for the pharmaceutical and biotechnology industry. It works with partners to discover medicines for difficult-to-treat diseases using integrated technology platforms.
- Status
- Uplisting
- Ticker
- EVO
- Exchange
- Nasdaq Global Select
- Listed
- Nov 5, 2021
- Price
- $21.75 per ADS
- Raised
- $435M
- Market cap at IPO price
- $3.8B
- First filed
- Oct 8, 2021
- Underwriters
- BofA Securities, Morgan Stanley, Citigroup, Jefferies, TD Cowen and RBC Capital Markets
- Company counsel
- Freshfields and Kirkland & Ellis
- Underwriters' counsel
- Latham & Watkins
- Sector
- Biotech & pharma
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Oct 8, 2021
- Latest amendment Oct 29, 2021
- Final prospectus (424B4) Nov 5, 2021
- All filings on EDGAR CIK 1412558
Other Biotech & pharma uplistings in 2021
- Creative Medical Technology Holdings, Inc.CELZ · Dec 6, 2021 · $16M
- Zivo Bioscience, Inc.ZIVO · Jun 1, 2021 · $13.8M
- Nexentis Technologies Inc.SVFD · May 17, 2021 · $12M
- Protagenic Therapeutics, Inc.\newPTIX · Apr 28, 2021 · $13.2M
- GT Biopharma, Inc.GTBP · Feb 12, 2021 · $23.6M
- Lexaria Bioscience Corp.LEXX · Jan 14, 2021 · $9.6M